Graphite Bio (NASDAQ:GRPH) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.30) by 16.67 percent.
Piper Sandler Initiates Coverage On Vicarious Surgical with Overweight Rating, Announces Price Target of $16
Piper Sandler analyst Adam Maeder initiates coverage on Vicarious Surgical (NYSE:RBOT) with a Overweight rating and announces Price Target of $16.